X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs NOVARTIS - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA NOVARTIS ASTRAZENECA PHARMA/
NOVARTIS
 
P/E (TTM) x 104.6 361.2 29.0% View Chart
P/BV x 14.9 17.8 83.8% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 ASTRAZENECA PHARMA   NOVARTIS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
NOVARTIS
Mar-16
ASTRAZENECA PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,285982 130.9%   
Low Rs634556 114.0%   
Sales per share (Unadj.) Rs189.6252.9 75.0%  
Earnings per share (Unadj.) Rs-0.262.1 -0.3%  
Cash flow per share (Unadj.) Rs3.863.3 6.1%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs68.6363.6 18.9%  
Shares outstanding (eoy) m25.0031.96 78.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.0 166.4%   
Avg P/E ratio x-4,712.712.4 -38,078.4%  
P/CF ratio (eoy) x249.612.2 2,053.9%  
Price / Book Value ratio x14.02.1 660.9%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m23,98824,580 97.6%   
No. of employees `0001.60.8 207.3%   
Total wages/salary Rs m1,6051,801 89.1%   
Avg. sales/employee Rs Th3,040.210,748.9 28.3%   
Avg. wages/employee Rs Th1,029.22,395.2 43.0%   
Avg. net profit/employee Rs Th-3.32,641.1 -0.1%   
INCOME DATA
Net Sales Rs m4,7408,083 58.6%  
Other income Rs m92829 11.1%   
Total revenues Rs m4,8328,913 54.2%   
Gross profit Rs m-130234 -55.4%  
Depreciation Rs m10137 275.7%   
Interest Rs m02 0.0%   
Profit before tax Rs m-1391,025 -13.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m1391,696 8.2%   
Tax Rs m5752 0.7%   
Profit after tax Rs m-51,986 -0.3%  
Gross profit margin %-2.72.9 -94.5%  
Effective tax rate %-3.773.4 -5.0%   
Net profit margin %-0.124.6 -0.4%  
BALANCE SHEET DATA
Current assets Rs m2,72612,678 21.5%   
Current liabilities Rs m2,4352,433 100.1%   
Net working cap to sales %6.1126.7 4.9%  
Current ratio x1.15.2 21.5%  
Inventory Days Days7433 225.6%  
Debtors Days Days4122 181.3%  
Net fixed assets Rs m1,03569 1,496.1%   
Share capital Rs m50160 31.3%   
"Free" reserves Rs m94211,460 8.2%   
Net worth Rs m1,71611,621 14.8%   
Long term debt Rs m00-   
Total assets Rs m4,15614,400 28.9%  
Interest coverage xNM570.5-  
Debt to equity ratio x00-  
Sales to assets ratio x1.10.6 203.2%   
Return on assets %-0.113.8 -0.9%  
Return on equity %-0.317.1 -1.7%  
Return on capital %023.6 0.0%  
Exports to sales %5.70.7 765.5%   
Imports to sales %6.518.6 34.8%   
Exports (fob) Rs m27060 448.8%   
Imports (cif) Rs m3061,503 20.4%   
Fx inflow Rs m375186 201.1%   
Fx outflow Rs m4701,821 25.8%   
Net fx Rs m-96-1,635 5.8%   
CASH FLOW
From Operations Rs m-82,531 -0.3%  
From Investments Rs m-146-8,270 1.8%  
From Financial Activity Rs m862-386 -223.5%  
Net Cashflow Rs m709-6,125 -11.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 0.3 2.0 15.0%  
FIIs % 15.7 1.6 981.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.5 42.3%  
Shareholders   12,856 41,647 30.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  SUVEN LIFE  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS